Sign In

Lawrence Lamb

Executive Vice President and Chief Scientific Officer at IN8bio, Inc.

Lawrence Lamb is a distinguished scientist and executive in the field of cell-based immunotherapy for cancer. He currently serves as the Executive Vice President and Chief Scientific Officer at IN8bio, a position he has held since January 2019.12

Career Highlights

Dr. Lamb's career spans over three decades in academia and industry. Prior to his current role at IN8bio, he held several notable positions:

  • Professor of Medicine at the University of Alabama at Birmingham (UAB) from April 2004 to December 20181
  • Director of the UAB Cell Therapy Laboratory in the Bone Marrow Transplant and Cellular Therapy department2
  • Associate Professor of Pediatrics at the University of South Carolina School of Medicine from 2000 to 20041
  • Assistant Professor of Medicine at the University of South Carolina School of Medicine from 1995 to 20001

Research Focus

Dr. Lamb's primary research interest is in cell-based immunotherapy for cancer. His work has been particularly influential in the study of gamma/delta T cells:

  • He was the first to describe an association between gamma/delta T cell recovery and disease-free survival in allogeneic bone marrow transplantation patients1
  • His current focus includes the biology of gamma/delta T cell interaction with high-grade gliomas and therapeutic gamma/delta T cell manufacturing strategies1

Education and Achievements

Dr. Lamb has an impressive educational background:

  • Ph.D. and M.S. from the University of South Carolina-Columbia
  • B.S. from the Medical College of Georgia
  • Completed postdoctoral fellowships in Molecular Genetics and Transplantation Immunology2

In October 2020, he was honored as a Distinguished Alumnus in Biomedical Science by the University of South Carolina School of Medicine.1

Current Role

At IN8bio, Dr. Lamb leads the scientific and translational strategy as a co-founder of the company.1 He continues to be active in the field, recently discussing research and data on gamma-delta T cells and their potential in cancer immunotherapy at a conference in April 2024.3

Highlights

May 23 · GlobeNewswire
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO ... - GlobeNewswire
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2
May 23 · Yahoo Finance
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO ... - Yahoo Finance
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2

Related Questions

What are Lawrence Lamb's main research interests at IN8bio?
How did Lawrence Lamb contribute to the University of Alabama at Birmingham?
What are some notable achievements of Lawrence Lamb in the field of cancer immunotherapy?
What is the significance of gamma-delta T cells in Lawrence Lamb's research?
How has Lawrence Lamb's role evolved since joining IN8bio?
Lawrence Lamb
Lawrence Lamb, photo 1
Lawrence Lamb, photo 2
Add to my network

Location

New York, New York, United States